• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 25-NSE filed by Forbion European Acquisition Corp.

    10/31/23 5:07:48 PM ET
    $FRBN
    Blank Checks
    Finance
    Get the next $FRBN alert in real time by email
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    UNITED STATES
    OMB APPROVAL
    OMB Number: 3235-0080
    Expires: March 31, 2018
    Estimated average burden
    hours per response: 1.7
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 25
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
    UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    Commission File Number 333-261308
    Issuer: Forbion European Acquisition Corp.
    Exchange: Nasdaq Stock Market LLC
    (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
    Address: 4001 Kennett Pike
    Suite 302
    Wilmington DELAWARE 19807
    Telephone number: +31 35 699 30 20
    (Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
    Class A Ordinary Shares, Warrants, Units
    (Description of class of securities)
    Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
    17 CFR 240.12d2-2(a)(1)
    17 CFR 240.12d2-2(a)(2)
    17 CFR 240.12d2-2(a)(3)
    17 CFR 240.12d2-2(a)(4)
    Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
    Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
    Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
    2023-10-31 By Tara Petta AVP
    Date Name Title
    1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $FRBN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FRBN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $FRBN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Forbion Growth Sponsor Feac I B.V. returned 3,373,496 units of Class A Ordinary Shares to the company (SEC Form 4)

    4 - Forbion European Acquisition Corp. (0001874495) (Issuer)

    10/31/23 7:05:31 PM ET
    $FRBN
    Blank Checks
    Finance

    Forbion Growth Sponsor Feac I B.V. converted options into 1,373,496 units of Class A Ordinary Shares (SEC Form 4)

    4 - Forbion European Acquisition Corp. (0001874495) (Issuer)

    10/31/23 6:59:26 PM ET
    $FRBN
    Blank Checks
    Finance

    New insider Forbion Growth Sponsor Feac I B.V. claimed ownership of 2,000,000 units of Class A Ordinary Shares (SEC Form 3) (Amendment)

    3/A - Forbion European Acquisition Corp. (0001874495) (Issuer)

    10/31/23 6:12:51 PM ET
    $FRBN
    Blank Checks
    Finance

    $FRBN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    enGene Appoints Richard Bryce, MBChB, MRCGP, MFPM, as Chief Medical Officer

    BOSTON and MONTREAL, Sept. 7, 2023 /PRNewswire/ - enGene, Inc., a clinical-stage biotechnology company mainstreaming gene therapy through its novel platform for the delivery of therapeutics to mucosal tissues and other organs, today announced the appointment of Richard Bryce, MBChB, MRCGP, MFPM as its Chief Medical Officer, effective September 19, 2023. Dr. Bryce will oversee the clin­i­cal develop­ment of EG-70, enGene's lead product candidate for non-muscle invasive bladder cancer (NMIBC), as well as the devel­op­ment strat­e­gy for enGene's ther­a­peu­tic pipeline of tissue-targeted non-viral gene therapies.

    9/7/23 7:00:00 AM ET
    $FRBN
    Blank Checks
    Finance

    enGene, Inc. and Forbion European Acquisition Corp. ("FEAC", Nasdaq: FRBN) Announce Business Combination Agreement to Create Nasdaq-Listed Biotechnology Company Developing Next-Generation Non-Viral, Locally Administered Gene Therapies

    Leading institutional investors commit $135 million USD in transaction financing, anchored by FEAC's sponsor, Forbion Growth Sponsor FEAC I B.V. (together with its parent entity Forbion Growth Opportunities Fund I Cooperatief U.A., "Forbion Growth").enGene is a clinical-stage biotechnology company developing non-viral gene therapies based on its proprietary dually derivatized chitosan ("DDX") platform that are re-dosable, manufacturable at scale and designed to be seamlessly integrated into community clinical practices across the globe.Net proceeds are expected to be used to finance enGene's operations through multiple potential value inflection milestones towards a potential Biologics Licen

    5/17/23 7:00:28 AM ET
    $FRBN
    Blank Checks
    Finance

    VectivBio Announces Results of Extraordinary General Meeting

    BASEL, Switzerland, Dec. 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, announced today that Wouter Joustra was elected as a new member of the Board of Directors at the Extraordinary General Meeting held on December 9, 2022. Mr. Wouter Joustra brings a breadth of capital markets and investment experience in the life sciences investment industry to VectivBio. He joined Forbion, a leading European life sciences venture capital firm, in October 2019, where he is currently General Partner. At Forbion, Mr. Joustra is responsible for deal originatio

    12/9/22 4:01:00 PM ET
    $FRBN
    $VECT
    Blank Checks
    Finance
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FRBN
    SEC Filings

    View All

    SEC Form 15-12G filed by Forbion European Acquisition Corp.

    15-12G - Forbion European Acquisition Corp. (0001874495) (Filer)

    11/13/23 6:45:16 AM ET
    $FRBN
    Blank Checks
    Finance

    Forbion European Acquisition Corp. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Changes in Control of Registrant, Material Modification to Rights of Security Holders, Regulation FD Disclosure

    8-K - Forbion European Acquisition Corp. (0001874495) (Filer)

    11/1/23 5:53:05 PM ET
    $FRBN
    Blank Checks
    Finance

    SEC Form 25-NSE filed by Forbion European Acquisition Corp.

    25-NSE - Forbion European Acquisition Corp. (0001874495) (Subject)

    10/31/23 5:07:48 PM ET
    $FRBN
    Blank Checks
    Finance

    $FRBN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Forbion European Acquisition Corp. (Amendment)

    SC 13G/A - Forbion European Acquisition Corp. (0001874495) (Subject)

    2/14/24 4:55:28 PM ET
    $FRBN
    Blank Checks
    Finance

    SEC Form SC 13G filed by Forbion European Acquisition Corp.

    SC 13G - Forbion European Acquisition Corp. (0001874495) (Subject)

    2/14/24 6:00:38 AM ET
    $FRBN
    Blank Checks
    Finance

    SEC Form SC 13G/A filed by Forbion European Acquisition Corp. (Amendment)

    SC 13G/A - Forbion European Acquisition Corp. (0001874495) (Subject)

    2/8/24 12:51:47 PM ET
    $FRBN
    Blank Checks
    Finance

    $FRBN
    Leadership Updates

    Live Leadership Updates

    View All

    enGene Appoints Richard Bryce, MBChB, MRCGP, MFPM, as Chief Medical Officer

    BOSTON and MONTREAL, Sept. 7, 2023 /PRNewswire/ - enGene, Inc., a clinical-stage biotechnology company mainstreaming gene therapy through its novel platform for the delivery of therapeutics to mucosal tissues and other organs, today announced the appointment of Richard Bryce, MBChB, MRCGP, MFPM as its Chief Medical Officer, effective September 19, 2023. Dr. Bryce will oversee the clin­i­cal develop­ment of EG-70, enGene's lead product candidate for non-muscle invasive bladder cancer (NMIBC), as well as the devel­op­ment strat­e­gy for enGene's ther­a­peu­tic pipeline of tissue-targeted non-viral gene therapies.

    9/7/23 7:00:00 AM ET
    $FRBN
    Blank Checks
    Finance